发布求助
文献互助 智能选刊 最新文献

Expert Opinion on Emerging Drugs最新文献

筛选
英文 中文
Challenges and limitations of mesenchymal stem cell therapy for lung diseases in clinical trials.
IF 2.7 3区 医学
Expert Opinion on Emerging Drugs Pub Date : 2025-04-07 DOI: 10.1080/14728214.2025.2489700
Mayck Medeiros Amaral da Silva, Patricia Rieken Macedo Rocco, Fernanda Ferreira Cruz
{"title":"Challenges and limitations of mesenchymal stem cell therapy for lung diseases in clinical trials.","authors":"Mayck Medeiros Amaral da Silva, Patricia Rieken Macedo Rocco, Fernanda Ferreira Cruz","doi":"10.1080/14728214.2025.2489700","DOIUrl":"10.1080/14728214.2025.2489700","url":null,"abstract":"","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"1-4"},"PeriodicalIF":2.7,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring psilocybin's role in mental health and palliative medicine: a path to improved well-being.
IF 2.7 3区 医学
Expert Opinion on Emerging Drugs Pub Date : 2025-04-03 DOI: 10.1080/14728214.2025.2488786
Maria-Alejandra Umbacia, Marta Ximena Leon, Jose-Manuel Quintero, Lina-Maria Castro, Veronica Paez, Seetal Dodd, Rosa-Helena Bustos
{"title":"Exploring psilocybin's role in mental health and palliative medicine: a path to improved well-being.","authors":"Maria-Alejandra Umbacia, Marta Ximena Leon, Jose-Manuel Quintero, Lina-Maria Castro, Veronica Paez, Seetal Dodd, Rosa-Helena Bustos","doi":"10.1080/14728214.2025.2488786","DOIUrl":"https://doi.org/10.1080/14728214.2025.2488786","url":null,"abstract":"<p><strong>Introduction: </strong>Although long known for their psychoactive effects, psychedelic drugs have only recently been investigated for medicinal use. Psilocybin has attracted the greatest interest with studies suggesting that it may be a useful agent in psychiatry and in palliative care.</p><p><strong>Areas covered: </strong>Clinical trials that included psilocybin were searched in PubMed, Embase, and ClinicalTrials.gov, demonstrating that adult psychiatry and palliative care are the medical fields that show the greatest interest in psilocybin treatment.</p><p><strong>Expert opinion: </strong>Psilocybin is a powerful drug that needs to be used with caution but may benefit some patients, including when other options have failed. It is best evidenced in treatment resistant depression and in palliative care, where patients are usually treated in specialist care centers. It has a novel mechanism of action, targeting the 5HT2A receptor, and can show rapid onset of action. There are many questions regarding its use that remain to be clarified, including its efficacy for other indications and its role as adjunctive treatment in psychotherapy. The psychoactive, or psychedelic effects are well documented, but their clinical importance is disputed.</p>","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An update on emerging anti-amyloid-β monoclonal antibodies for treating Alzheimer's disease: the role of apolipoprotein E. 治疗阿尔茨海默病的新型抗淀粉样蛋白-β单克隆抗体的最新进展：脂蛋白E的作用。
IF 2.7 3区 医学
Expert Opinion on Emerging Drugs Pub Date : 2025-03-26 DOI: 10.1080/14728214.2025.2481847
Madia Lozupone, Vittorio Dibello, Antonio Daniele, Francesco Panza
{"title":"An update on emerging anti-amyloid-β monoclonal antibodies for treating Alzheimer's disease: the role of apolipoprotein E.","authors":"Madia Lozupone, Vittorio Dibello, Antonio Daniele, Francesco Panza","doi":"10.1080/14728214.2025.2481847","DOIUrl":"10.1080/14728214.2025.2481847","url":null,"abstract":"","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"1-5"},"PeriodicalIF":2.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder.
IF 2.7 3区 医学
Expert Opinion on Emerging Drugs Pub Date : 2025-02-23 DOI: 10.1080/14728214.2025.2470706
Edgar Carnero Contentti, Jorge Correale
{"title":"Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder.","authors":"Edgar Carnero Contentti, Jorge Correale","doi":"10.1080/14728214.2025.2470706","DOIUrl":"https://doi.org/10.1080/14728214.2025.2470706","url":null,"abstract":"","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging treatments for sarcoma: from 2024 onward.
IF 2.7 3区 医学
Expert Opinion on Emerging Drugs Pub Date : 2025-02-03 DOI: 10.1080/14728214.2025.2460525
Diego Gómez-Puerto, Carlo M Cicala, Claudia Valverde, César Serrano
{"title":"Emerging treatments for sarcoma: from 2024 onward.","authors":"Diego Gómez-Puerto, Carlo M Cicala, Claudia Valverde, César Serrano","doi":"10.1080/14728214.2025.2460525","DOIUrl":"10.1080/14728214.2025.2460525","url":null,"abstract":"<p><strong>Introduction: </strong>Sarcomas are a rare and diverse group of mesenchymal-origin solid tumors, constituting only 1% of adult malignancies and classified into soft tissue and bone sarcomas. For localized diseases, surgery and radiotherapy remain the cornerstone treatments. However, systemic options for advanced stages are limited, with an overall survival of approximately 20 months. There is an urgent need to refine clinical trial designs and evaluate novel therapies to improve patient outcomes.</p><p><strong>Areas covered: </strong>This review summarizes recent advancements in sarcoma clinical trials, highlighting promising therapies that may reshape treatment paradigms. It also examines insights from comprehensive genomic profiling studies, which are paving the way for next-generation therapeutic approaches.</p><p><strong>Expert opinion: </strong>The heterogeneity and rarity of sarcomas present substantial challenges to the development and regulatory approval of effective therapies. Recent progress in the field has introduced innovative approaches, including novel chemotherapeutic agents, targeted therapies, and immunotherapeutics. However, despite these advancements, significant hurdles persist. While these strategies have demonstrated some success, the overall improvements in survival have often been modest, irrespective of the therapeutic modality. This underscores critical concerns regarding the true cost-benefit balance and the potential for adverse effects, particularly when evaluated over extended follow-up periods.</p>","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"1-18"},"PeriodicalIF":2.7,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging biological treatments for asthma.
IF 2.7 3区 医学
Expert Opinion on Emerging Drugs Pub Date : 2025-02-01 DOI: 10.1080/14728214.2025.2460529
Daniela Pastore, Chiara Lupia, Maria D'Amato, Andrea Bruni, Eugenio Garofalo, Federico Longhini, Luca Gallelli, Alessandro Vatrella, Girolamo Pelaia, Corrado Pelaia
{"title":"Emerging biological treatments for asthma.","authors":"Daniela Pastore, Chiara Lupia, Maria D'Amato, Andrea Bruni, Eugenio Garofalo, Federico Longhini, Luca Gallelli, Alessandro Vatrella, Girolamo Pelaia, Corrado Pelaia","doi":"10.1080/14728214.2025.2460529","DOIUrl":"10.1080/14728214.2025.2460529","url":null,"abstract":"<p><strong>Introduction: </strong>Severe asthma is a chronic airway disease characterized by many pathomechanisms known as endotypes. Biological therapies targeting severe asthma endotypes have significantly improved the treatment of this disease, thus remarkably bettering patient quality of life.</p><p><strong>Areas covered: </strong>This review aims to describe current biological therapies for severe asthma, highlighting emerging ones. Several studies have confirmed the beneficial effects of currently available monoclonal antibodies targeting immunoglobulin E (IgE), interleukin-5 (IL-5) or its receptor, and interleukin-4 (IL-4)/interleukin-13 (IL-13) receptors (IL-4R/IL-13R). However, patients with T2-low asthma are not eligible for the above biological therapies.</p><p><strong>Expert opinion: </strong>New treatments are now moving toward targeting the upstream pathways of asthma pathogenesis, coordinated by innate cytokines such as alarmins. These key proinflammatory mediators orchestrate the activation of complex cellular networks including both innate and adaptive immune responses. Alarmins include thymic stromal lymphopoietin (TSLP), interleukin-25 (IL-25), and interleukin-33 (IL-33), which are released from injured airway epithelial cells. TSLP and the other alarmins are suitable targets of biological therapies which are effective for add-on treatment of type 2 asthma. Moreover, anti-alarmin monoclonal antibodies can be also beneficial for patients with T2-low, poorly controlled severe asthma.</p>","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"1-11"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mitapivat: a step forward across different hemolytic diseases.
IF 2.7 3区 医学
Expert Opinion on Emerging Drugs Pub Date : 2025-01-29 DOI: 10.1080/14728214.2025.2458063
Mohammad Hassan Hodroj, Joseph Klim, Nicole Charbel, Ali Taher
{"title":"Mitapivat: a step forward across different hemolytic diseases.","authors":"Mohammad Hassan Hodroj, Joseph Klim, Nicole Charbel, Ali Taher","doi":"10.1080/14728214.2025.2458063","DOIUrl":"https://doi.org/10.1080/14728214.2025.2458063","url":null,"abstract":"","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"1-3"},"PeriodicalIF":2.7,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
FcRn inhibitors in the context of myasthenia gravis.
IF 2.7 3区 医学
Expert Opinion on Emerging Drugs Pub Date : 2025-01-28 DOI: 10.1080/14728214.2025.2458061
Deepak Menon, Vinaya Bhandari
{"title":"FcRn inhibitors in the context of myasthenia gravis.","authors":"Deepak Menon, Vinaya Bhandari","doi":"10.1080/14728214.2025.2458061","DOIUrl":"10.1080/14728214.2025.2458061","url":null,"abstract":"","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"1-4"},"PeriodicalIF":2.7,"publicationDate":"2025-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Muscarinic M1 and M4 agents as treatments for schizophrenia: what do they do and who do they do it for? 毒蕈碱M1和M4制剂作为精神分裂症的治疗：它们有什么作用，对谁有效？
IF 2.7 3区 医学
Expert Opinion on Emerging Drugs Pub Date : 2025-01-23 DOI: 10.1080/14728214.2025.2458053
Philip D Harvey
{"title":"Muscarinic M1 and M4 agents as treatments for schizophrenia: what do they do and who do they do it for?","authors":"Philip D Harvey","doi":"10.1080/14728214.2025.2458053","DOIUrl":"10.1080/14728214.2025.2458053","url":null,"abstract":"","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"1-5"},"PeriodicalIF":2.7,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systemic therapy for child-pugh B patients with hepatocellular carcinoma. 儿童B型肝癌患者的全身治疗。
IF 2.7 3区 医学
Expert Opinion on Emerging Drugs Pub Date : 2025-01-20 DOI: 10.1080/14728214.2025.2456774
Kevin Mok, Olivia Chen, Johnny Yau, Landon L Chan, Stephen L Chan
{"title":"Systemic therapy for child-pugh B patients with hepatocellular carcinoma.","authors":"Kevin Mok, Olivia Chen, Johnny Yau, Landon L Chan, Stephen L Chan","doi":"10.1080/14728214.2025.2456774","DOIUrl":"https://doi.org/10.1080/14728214.2025.2456774","url":null,"abstract":"","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143002928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信